NERV
NASDAQMinerva Neurosciences Inc
News · 26 weeks54-25%
2025-12-072026-05-31
Mix3390d
- SEC Filings19(58%)
- Other8(24%)
- Insider3(9%)
- Leadership2(6%)
- Analyst1(3%)
Latest news
25 items- PRMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company's PIPE financing announced on October 21, 2025. The SAB brings together distinguished researchers and clinicians with proven track records of advancing meaningful treatments in psychiatry and neuroscience. "The formation of this Scientific Advisory Board reflects our commitment to bringing the highest level of scientific rigor and clinical exp
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 424B5 filed by Minerva Neurosciences Inc424B5 - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceBURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. 2026 Jefferies Global Healthcare ConferenceFormat:Fireside chatDay/Time:Thursday, June 4 at 4:20 PM ETWebcast:Link here If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative. A replay of the presentat
- SECSEC Form SCHEDULE 13G filed by Minerva Neurosciences IncSCHEDULE 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 10-Q filed by Minerva Neurosciences Inc10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesConfirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported financial and business updates for the first quarter ended March 31, 2026. Business Updates Roluperidone - potenti
- SECSEC Form DEFA14A filed by Minerva Neurosciences IncDEFA14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form DEF 14A filed by Minerva Neurosciences IncDEF 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- INSIDERSEC Form 4 filed by O'Connor James Joseph4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 3 filed by new insider O'Connor James Joseph3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- ANALYSTCitizens initiated coverage on Minerva Neurosciences with a new price targetCitizens initiated coverage of Minerva Neurosciences with a rating of Mkt Outperform and set a new price target of $14.00
- SECSEC Form PRE 14A filed by Minerva Neurosciences IncPRE 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Announces Leadership TransitionBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant. Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President
- INSIDERSEC Form 4 filed by Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- PRMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaRoluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivat
- PRMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25
- SECSEC Form EFFECT filed by Minerva Neurosciences IncEFFECT - Minerva Neurosciences, Inc. (0001598646) (Filer)
NERV FAQ
7 questionsWhat does Minerva Neurosciences Inc do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import...Where does NERV stock trade?
Minerva Neurosciences Inc (NERV) is listed on NASDAQ.What sector and industry is NERV in?
Minerva Neurosciences Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Minerva Neurosciences Inc go public?
Minerva Neurosciences Inc (NERV) completed its IPO in 2014.What are analysts saying about NERV?
Minerva Neurosciences Inc has had 2 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $1400.00 price target on 2026-04-15. Recent price targets range from $500.00 to $1400.00.What companies are similar to NERV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NERV side-by-side with any of them on Quantisnow.How can I track NERV on Quantisnow?
Quantisnow aggregates Minerva Neurosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NERV to receive live email and push alerts on every new disclosure.